Back to Agenda
Session 5 - Preclinical Assessment
Session Chair(s)
Alan Bass, PhD
Senior Fellow, Exploratory Drug Safety
Schering-Plough Research Institute, United States
PRECLINICAL ASSESSMENT
Speaker(s)
WHAT ARE THE EXPECTATIONS OF THE PRECLINICAL SAFETY STUDIES OF MOLECULES IN DEVELOPMENT FOR T2D?
Alan Bass, PhD
Schering-Plough Research Institute, United States
Senior Fellow, Exploratory Drug Safety
THE ROLE OF IN-VITRO MODELS IN PREDICTING CV RISK (CELL SYSTEMS, CARDIAC MYOCYTES, ISOLATED TISSUES AND ORGANS)
Peter Hoffmann, MD, PhD
Novartis, United States
Executive Director Preclinical Safety
IN-VIVO ASSAYS FOR EARLY IDENTIFICATION OF CARDIOVASCULAR TOXICITIES DURING DRUG DISCOVERY
Paul C. Levesque, PhD
Bristol Myers Squibb, United States
Principal Scientist, Dept. of Cardiovascular Diseases
SUBCHRONIC AND CHRONIC TOXICOLOGY STUDIES IN JUDGING THE RISK OF CARDIOVASCULAR TOXICITY
Calvert Louden, DVM, PhD
Johnson and Johnson Pharmaceuticals, United States
Senior Director of Pathology
PANEL DISCUSSION: GAPS, CHALLENGES AND FUTURE DIRECTIONS FOR NON-CLINICAL ASSAYS/MODELS IN IDENTIFYING CV RISK OF T2DM MEDICATIONS – All Speakers Above And
Börje C. Darpö, MD, PhD
Clario, Sweden
Chief Scientific Officer, Cardiac Safety
Have an account?